Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 1
2019 3
2020 2
2021 4
2022 2
2023 3

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Results by year

Filters applied: . Clear all
Page 1
Bridging the knowledge gap of biomedical HIV prevention tools among sub-saharan african immigrants in France. Results from an empowerment-based intervention.
Coulibaly K, Bousmah MA, Ravalihasy A, Taéron C, Mbiribindi R, Senne JN, Gubert F, Gosselin A, Desgrées du Loû A; MAKASI Study Group. Coulibaly K, et al. Among authors: bousmah ma. SSM Popul Health. 2023 Jul 23;23:101468. doi: 10.1016/j.ssmph.2023.101468. eCollection 2023 Sep. SSM Popul Health. 2023. PMID: 37560089 Free PMC article.
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
Bousmah MA, Nishimwe ML, Tovar-Sanchez T, Lantche Wandji M, Mpoudi-Etame M, Maradan G, Omgba Bassega P, Varloteaux M, Montoyo A, Kouanfack C, Delaporte E, Boyer S; New Antiretroviral and Monitoring Strategies in HIV-infected Adults in Low-Income Countries (NAMSAL) ANRS 12313 Study Group. Bousmah MA, et al. Pharmacoeconomics. 2021 Mar;39(3):331-343. doi: 10.1007/s40273-020-00987-3. Epub 2020 Dec 23. Pharmacoeconomics. 2021. PMID: 33355914 Free PMC article.
Improvements in patient-reported outcomes following initiation of dolutegravir- or low-dose efavirenz-based first-line antiretroviral therapy: A four-year longitudinal analysis in Cameroon (NAMSAL ANRS 12313 trial).
Bousmah MA, Protopopescu C, Mpoudi-Etame M, Bassega PO, Maradan G, Olinga J, Varloteaux M, Tovar-Sanchez T, Delaporte É, Kouanfack C, Boyer S; NAMSAL ANRS 12313 Study Group. Bousmah MA, et al. J Acquir Immune Defic Syndr. 2023 Aug 14. doi: 10.1097/QAI.0000000000003273. Online ahead of print. J Acquir Immune Defic Syndr. 2023. PMID: 37643413
14 results